Lancashire and South Cumbria
Formulary
Formulary
7 Obstetrics, Gynaecology, and urinary-tract disorders
07-02-01 Non-hormonal preparations
| Fezolinetant |
|
Formulary
|
NICE TA expected in May 2025 |
 MHRA: Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk |
|
Links
- FSRH Clinical Guideline: Contraceptive Choices for Young People
- BMS: BMS statement in response to the publication of the updated NICE Menopause guideline (NG23)
- FSRH: Standards & Guidance
- FSRH: UK Medical Eligibility Criteria for Contraceptive Use (UKMEC)
LSCMMG: Erectile Dysfunction Guideline- LSCMMG: Overactive bladder in female adults
- MHRA: Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?
- NICE CG30: Long-acting reversible contraception
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management
- NICE NG133: Hypertension in pregnancy: diagnosis and management
- NICE NG194: Postnatal care
- NICE NG210: Pelvic floor dysfunction: prevention and non-surgical management
- NICE NG23: Menopause: identification and management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE NG88: Heavy menstrual bleeding: assessment and management